NAII

Business Context and Reporting Period

Company: Natural Alternatives International, Inc. (NAII)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal Year ended June 30, 2024
Business Overview: NAI is a leading formulator, manufacturer, and marketer of nutritional supplements. Its primary business consists of private-label contract manufacturing services and the commercialization of its beta-alanine patent estate (CarnoSyn®, SR CarnoSyn®, and TriBsyn™) through raw material sales and licensing. Operations are conducted primarily in Vista and Carlsbad, California, and Manno, Switzerland.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Decline: Net sales decreased 26% to $113.8 million. Private-label contract manufacturing sales dropped 27% due to reduced orders from major customers managing excess inventory and unfavorable Euro-to-USD exchange rates. Patent and trademark licensing revenue declined 3% to $8.4 million.
• Profitability Reversal: The company reported a net loss of $7.2 million in FY2024 compared to net income of $2.5 million in FY2023. Gross margin contracted by 5.8 percentage points, driven by unfavorable sales mix, lower volume spreading fixed costs, and higher per-unit manufacturing costs.
• Facility Operations: A high-speed powder processing facility in Carlsbad was temporarily closed from October 2023 to May 2024 due to a major customer's inventory rebalancing, contributing to increased fixed costs per unit.
• Expense Fluctuations: Selling, general, and administrative (SG&A) expenses increased 15% to $15.4 million. This increase is largely due to the absence of a $1.3 million Employee Retention Tax Credit benefit and a $1.4 million bad debt recovery recorded in FY2023.

Guidance, Outlook, and Risks

• Outlook: Management anticipates a net loss in the first half of fiscal 2025, net income in the second half, and a break-even or slight profit for the full fiscal 2025 year. Sales are forecast to increase significantly compared to FY2024.
• Strategic Focus: The company is launching TriBsyn™ to penetrate the Wellness and Healthy Aging channels and aims to diversify its customer base to reduce reliance on top clients.
• Liquidity and Debt Covenants: The company has $12.0 million in available borrowing capacity on its line of credit. However, management anticipates it will not be able to comply with all covenants under the amended credit agreement in the first half of fiscal 2025 and is currently negotiating a revised facility or waiver with its lender.
• Risks:
  • Customer Concentration: Three customers accounted for approximately 68% of consolidated net sales in FY2024. The loss of any major customer would have a material adverse effect.
  • Supply Chain: Reliance on a single supplier for beta-alanine and ongoing geopolitical tensions (Ukraine-Russia, Israel-Hamas) impacting raw material availability and costs.
  • Patent Expiration: Key patents for instant-release CarnoSyn® expire in 2026, necessitating successful commercialization of SR CarnoSyn® and TriBsyn™.

Investor Verification Checklist

• Covenant Compliance: Verify the status of negotiations with Wells Fargo regarding the anticipated covenant breach in H1 FY2025 and the terms of any revised credit facility.
• Customer Recovery: Monitor order volumes from the top three customers, particularly the client responsible for the Carlsbad facility closure, to confirm the anticipated sales rebound.
• TriBsyn™ Adoption: Assess early market acceptance and revenue contribution from the new TriBsyn™ product line as a hedge against the 2026 patent expiration.
• Margin Expansion: Track gross margin trends to ensure fixed costs are being absorbed by increased production volumes as the Carlsbad facility operates at full capacity.
• Foreign Exchange Exposure: Review the impact of EUR/USD and CHF/USD fluctuations on future earnings, given significant operations in Switzerland and Europe.